The Navy said the service's top admiral is "cancer-free" after surgery last summer and follow-up radiation therapy.

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

Each year in October, the National Breast Cancer Awareness Month campaign helps to educate the public about symptoms, risk ...

Drug treatments for blood cancers have evolved. In the past, myeloma patients received two drugs in sequence—two after two.

Get Organized with the Home Edit” star Clea Shearer opens up about how she finds new meaning in life two years after being ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

New evidence shows that extended estrogen suppression treatment using an aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of ...

New research identifies specific genetic changes that can increase a person's risk of breast and ovarian cancers, to help guide clinical decision-making.

A primary care healthcare provider will typically refer an individual to an oncologist if they suspect the person may have ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.